Related Experiment Videos

[Excitotoxic cascade and neuroprotection in various stages of cerebral development]

P Evrard1, S Marret, P Gressens

  • 1Service de Neurologie pédiatrique, CRI INSERM 96-03, Hôpital Robert-Debré, faculté de Médecine Xavier-Bichat, Université de Paris VII.

Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique
|January 1, 1997
PubMed

Insights

Cerebral palsy prevalence is rising due to multifactorial causes affecting perinatal brain development. New neuroprotective drugs targeting excitotoxicity offer hope for neonatal brain injury prevention.

Area of Science:

  • Neurology
  • Developmental Pediatrics
  • Perinatal Medicine

Context:

  • Increasing prevalence of cerebral palsy in Western countries necessitates updated understanding.
  • Perinatal brain lesions are a key focus in current research.
  • Etiology is recognized as multifactorial, involving various insults.

Purpose:

  • To review the pathophysiology and etiology of perinatal brain lesions contributing to cerebral palsy.
  • To highlight the role of excitotoxicity as a common pathway in neural cell death.
  • To introduce emerging pharmacological strategies for neonatal neuroprotection.

Summary:

  • Cerebral palsy incidence has significantly increased, driven by complex factors including hypoxia, preconceptional issues, hormonal deficiencies, and maternal infections.
  • The excitotoxic cascade, mediated by excitatory amino acids, is identified as a critical mechanism leading to neuronal damage.
  • Novel pharmacological agents designed to inhibit excitotoxicity show promise for protecting the neonatal brain.

Impact:

  • Advances understanding of cerebral palsy's complex origins.
  • Identifies excitotoxicity as a therapeutic target for neonatal brain injury.
  • Offers potential for improved neuroprotective strategies in newborns at risk.

Related Concept Videos